Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 19, Issue 9, 2009, Pages 634-640

  de Simone, G ^a,b   Okin, P M ^b   Gerdts, E ^c   Olsen, M H ^d   Wachtell, K ^d   Hille, D A ^e   Dahlof B ^f   Kjeldsen, S E ^g   Devereux, R B ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF BERGEN   (Norway)

^d GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^e MERCK RESEARCH LABORATORIES   (United States)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Diabetes; Echocardiography; Electrocardiography; Hypertension; Obesity; Plasma cholesterol

Indexed keywords

EID: 70350755561     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2008.12.012     Document Type: Article

References (28)

1. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
2. de Simone G., Olsen M.H., Wachtell K., Hille D.A., Dahlof B., Ibsen H., et al. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. J Hum Hypertens 21 (2007) 625-632
3. Chinali M., Devereux R.B., Howard B.V., Roman M.J., Bella J.N., Liu J.E., et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart study). Am J Cardiol 93 (2004) 40-44
4. Arcucci O., de Simone G., Izzo R., Rozza F., Chinali M., Rao M.A., et al. Association of suboptimal blood pressure control with body size and metabolic abnormalities. J Hypertens 25 (2007) 2296-2300
5. Okin P.M., Devereux R.B., Gerdts E., Snapinn S.M., Harris K.E., Jern S., et al. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in hypertension study. Circulation 113 (2006) 1588-1596
6. Dahlof B., Devereux R.B., de Faire U., Fyhrquist F., Hedner T., Ibsen H., et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study. Am J Hypertens 10 (1997) 705-713
7. Dahlof B., Devereux R.B., Julius S., Kjeldsen S.E., Beevers G., de Faire U., et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Hypertension 32 (1998) 989-997
8. de Simone G., Wachtell K., Palmieri V., Hille D.A., Beevers G., Dahlof B., et al. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. Circulation 111 (2005) 1924-1931
9. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285 (2001) 2486-2497
10. Puavilai G., Chanprasertyotin S., and Sriphrapradaeng A. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization. Diabetes Res Clin Pract 44 (1999) 21-26
11. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131 (1999) 281-303
12. Okin P.M., Devereux R.B., Jern S., Kjeldsen S.E., Julius S., Nieminen M.S., et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study. Circulation 108 (2003) 684-690
13. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
14. Devereux R.B., Dahlof B., Gerdts E., Boman K., Nieminen M.S., Papademetriou V., et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 110 (2004) 1456-1462
15. Devereux R.B., Bella J., Boman K., Gerdts E., Nieminen M.S., Rokkedal J., et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Blood Press 10 (2001) 74-82
16. Devereux R.B., Wachtell K., Gerdts E., Boman K., Nieminen M.S., Papademetriou V., et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292 (2004) 2350-2356
17. Sahn D.J., DeMaria A., Kisslo J., and Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58 (1978) 1072-1083
18. Schiller N.B., Shah P.M., Crawford M., DeMaria A., Devereux R.B., Feigenbaum H., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
19. Devereux R.B., Alonso D.R., Lutas E.M., Gottlieb G.J., Campo E., Sachs I., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57 (1986) 450-458
20. Okin P.M., Devereux R.B., Harris K.E., Jern S., Kjeldsen S.E., Lindholm L.H., et al. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. Hypertension 50 (2007) 984-990
21. Sokolow M., and Lyon T.P. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 37 (1949) 161-186
22. Dunn R.A., Pipberger H.V., Holt Jr. J.H., Barnard A.C., and Pipberger H.A. Performance of conventional orthogonal and multiple-dipole electrocardiograms in estimating left ventricular muscle mass. Circulation 60 (1979) 1350-1353
23. Schillaci G., Pirro M., Pucci G., Mannarino M.R., Gemelli F., Siepi D., et al. Different impact of the metabolic syndrome on left ventricular structure and function in hypertensive men and women. Hypertension 47 (2006) 881-886
24. Mule G., Cusimano P., Nardi E., Cottone S., Geraci C., Palermo A., et al. Relationships between metabolic syndrome and left ventricular mass in hypertensive patients: does sex matter?. J Hum Hypertens 22 (2008) 788-795
25. Escobar C., Barrios V., Calderon A., Barrios S., Echarri R., Navarro-Cid J., et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA study. J Clin Hypertens 10 (2008) 208-214
26. Mule G., Nardi E., Cottone S., Cusimano P., Volpe V., Piazza G., et al. Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med 257 (2005) 503-513
27. de Simone G., Devereux R.B., Chinali M., Best L.G., Lee E.T., Galloway J.M., et al. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart study. Diabetes Care 30 (2007) 1851-1856
28. de Simone G., Devereux R.B., Chinali M., Roman M.J., Lee E.T., Resnick H.E., et al. Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the Strong Heart study. Nutr Metab Cardiovasc Dis (2008) [epub ahead of print]